InvestorsHub Logo
Followers 36
Posts 2689
Boards Moderated 0
Alias Born 06/09/2011

Re: abeta post# 104263

Friday, 02/24/2017 12:09:44 PM

Friday, February 24, 2017 12:09:44 PM

Post# of 692388
Bingo abeta!!!! Doc logic has great understanding of CXCR-4 as it relates to what NWBO is doing with this patent. You can my highlights in your quote in bold!

Message in reply to:

NWBO Patent 9,566,294 February 14, 2017 - full deck - so to speak

EDIT

Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

Quote:
The present invention further relates to the Applicants' findings that CXCR-4 (SEQ ID NO:2) is over-expressed in several brain tumor derived cell lines and primary brain tumor tissues, including neuroblastoma and neuroectodermal human tumor cell lines, medulloblastoma and astrocytoma grade III cell lines, and primary glioma and meningioma tumors. Further, CXCR-4 (SEQ ID NO:2) was found to be over-expressed in breast tumor tissues, lymphoblastic leukemia cell lines, Burkitt's lymphoma cell lines, colorectal adenocarcinomas, lung carcinoma, and melanoma cell lines.

out of my depth but one or more lurkers may be curious ....

62 pages .....


insert-text-here

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News